Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Capital Expenditures history
Currency unavailable · from the cash flow
No Capital Expenditures data reported for this period type.
Capital Expenditures vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $783K USD | -14.8% | +13.7% | 0.4% | |
| LTM Mar 2026 | $497K USD | -35.3% | -14.1% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $496K USD | +19.8% | +25.1% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $411K USD | -74.7% | +29.4% | 2.1% |
| LTM Mar 2026 | $181.36K USD | +342.3% | +21.8% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $78K USD | — | — | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $16K USD | — | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | -14.8% | +21.8% | 1.2% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.